Skip Navigation LinksHome > June 1, 2011 - Volume 57 - Issue 2 > Survival in XDR TB: Shifting the Curve and Shifting the Para...
Text sizing:
A
A
A
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0b013e31821b4b42
Invited Review

Survival in XDR TB: Shifting the Curve and Shifting the Paradigm

Martinson, Neil A MBBCh, MPH*† ; Chaisson, Richard E MD*

Free Access
Article Outline
Collapse Box

Author Information

From the *Johns Hopkins University Center for TB Research, Baltimore, MD; and †Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.

The authors Drs N.A.M. and R.E.C. receive funding from NHLBI R01 HL090312, NICHD R01 HD064354, and the Centers for Disease Control and Prevention CDC 200-2009-32589. Dr N.A.M. is partially funded by National Institutes of Health Fogarty International Center grants RTW007373 and RTW007370.

The authors have no conflicts of interest to disclose.

The article by Kvasnovsky et al1 in this issue of JAIDS: J Acquir Immune Defic Syndr describing the dismal treatment outcomes of patients with extensively drug-resistant tuberculosis (TB) in the Eastern Cape of South Africa—a setting with a high prevalence of HIV and an extremely high TB burden—is a ghastly reminder of the toll exacted by this explosive public health crisis. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB have derailed the relatively few gains made in TB control in areas such as South Africa with high HIV prevalence. It is no surprise that South Africa, with its high incidence of active TB (almost 1% of South Africa's 50 million people were diagnosed with TB in 20092) and its historically high rates of poor treatment outcomes, should also have a large number of individuals with drug-resistant TB. Drug-resistant Mycobacterium tuberculosis does not exist in nature—it is the product of human intervention, selected by inappropriate or inadequate treatment and poor adherence. XDR TB-MDR TB that has acquired resistance to second-line drugs for TB including the fluoroquinolones and at least one so-called injectable agent—is the product of mismanagement of MDR TB. In South Africa, the mistakes of the past are amplified by the large number of people rendered profoundly susceptible to TB by HIV infection, compounded by ongoing weaknesses in TB control. A significant proportion of individuals with MDR and XDR TB have never had exposure to the selective pressure of TB treatment and appear likely to have been initially infected with a resistant strain.3,4 When drug-resistant TB develops, delays in diagnosis and initiation of appropriate treatment exacerbate an already terrible situation by amplification of resistance, ongoing transmission of infection in the community (and health institutions), and rapid progression of disease to death.

The article by Kvasnovsky et al1 highlights several important challenges in responding to drug-resistant TB. First, the prognosis of patients with XDR is extremely poor, irrespective of HIV serostatus; one quarter of the XDR TB patients reported in this study died before they received any treatment for XDR, and many of these are likely to have been co-infected with HIV. HIV-seronegative patients comprised a large proportion (45%) of those who survived to receive XDR TB therapy, but over half had died within 2 years of diagnosis. HIV-infected patients treated for XDR TB who did not receive antiretroviral therapy (ART) had extremely poor survival, with only a third surviving to 1 year. As a comparison, Harries et al5 reported that 23% of patients with all forms of TB died during TB treatment in Malawi in 1997. Those fortunate enough to have been started on ART in the current study had a similar survival to HIV-seronegative XDR patients, but this should be viewed as “equally bad” rather than “equally good.” Two landmark trials comparing optimal timing of ART initiation in relation to TB therapy in HIV-infected adults have clearly shown that early initiation of ART reduces mortality—an effect apparent at both high and low CD4 counts.6,7 Differences in prognosis by HIV serostatus and ART reported here are similar to a larger retrospective report from 4 treatment centers in South Africa8 (which seems to include at least some of the patients in the Kvasnovsky article). The survival data reported here—particularly the pre-XDR treatment mortality rate—are better than those in the report which sounded the initial alarm of the potential threat of XDR to HIV-infected adults. Gandhi et al3 described short-term outcomes in patients diagnosed at a general hospital in the KwaZulu Natal, Province—neighboring the Eastern Cape Province—about 2 years before those in this article. The authors reported that 52 of 53 XDR patients in their study died, 70% within a month of the diagnostic specimen being taken and that all who were HIV tested were HIV seropositive. In both settings mortality is unacceptably high, underscoring the urgent need for new approaches to managing MDR and XDR TB.

New drugs and new regimens of drug combinations are desperately needed to treat drug-resistant TB. The recent publication of a randomized trial of the novel ATP synthase inhibitor TMC207 in MDR TB patients was an important step forward.9 Testing of this and other novel TB agents should include both HIV-infected individuals and children if these products are to be used in these populations. Successful regimens for drug-resistant TB require a variety of drugs. They will likely include the following: new agents, such as TMC 207, OPC-67683,10 and PA-82411; repurposed drugs, such as respiratory fluoroquinolones; and optimized old drugs, including isoniazid and pyrazinamide. Although the world waits in eager anticipation of the novel agents, existing agents are not being optimally used or may be misused. For example, it is abundantly clear that moxifloxacin is a potent fluoroquinolone12—more so than ofloxacin13—but many programs continue to use ofloxacin because it is less expensive, contributing to treatment failure and the selection of fluoroquinolone-resistant organisms. In addition, there is reason to believe that high-dose isoniazid may be effective in treating organisms with mutations in the inhA gene,14 and this could improve and shorten regimens for MDR and XDR TB.

Second, the authors highlight delays in diagnosis of XDR TB; patients in this retrospective cohort had a mean of 15.7 months of TB treatment before XDR diagnosis and cohort entry. Delays in the clinical triggers to suspect and investigate drug-resistant TB, which could be fatal, are compounded by the built-in tardiness of culture-based drug sensitivity testing for first and then second-line TB drugs. The line probe assay (Genotype MTBDRplus) which has been made available in several high through-put laboratories in South Africa offers some hope of overcoming lengthy delays in diagnosis of MDR TB and also rapidly confirms infection with M. tuberculosis.15 Unfortunately, its usefulness is restricted to smear-positive cases, thereby excluding most HIV-infected individuals with TB who are likely to be smear negative. The recently described Xpert MTB/RIF real-time polymerase chain reaction assay has enormous potential to identify both M. tuberculosis infection and genotypic rifampin resistance,16 but expense may limit widespread implementation.

A further issue that complicates management of TB treatment is the possibility of re-infection with another M. tuberculosis strain during and after treatment, quite possibly in the clinics or hospitals where patients are receiving their MDR or XDR TB therapy. Although confining patients in sanatoria may prevent spread of resistant TB in the community, the risk of transmission is likely still present, not only between patients but also to health workers who seem to be at higher risk of being admitted to hospital with XDR TB than the populations they serve.17

Finally, reports such as the one in this issue, of programmatic outcomes, are bedeviled by their retrospective and incomplete nature and describe only a subset of patients who not only survive long delays before being diagnosed with MDR or XDR TB but then have to reach specialist public sector treatment programs which are often long distances from their homes. Highlighting this diagnostic gap is a postmortem biopsy study with mycobacterial culture and drug sensitivity testing conducted at a hospital in KwaZulu Natal that showed 17% of cadavers dying from “natural” causes were infected with MDR TB; only 1 was on MDR treatment before death.18 There is clearly a pressing need for much improved surveillance of all forms of TB in high-burden countries, including all diagnosed cases, deaths, and treated patients. Currently, only patients who enroll in directly observed therapy, short course programs are reported in many high-incidence countries, excluding mortality statistics to monitor and assess progress—or the lack thereof.

Important public health and epidemiological lessons have been learnt from the XDR TB epidemic. However, research and control efforts must continue to address all forms of TB, including the approximately 93% of patients who do not have drug-resistant TB. Earlier identification of cases of TB by active case finding,19,20 together with rapid routine drug sensitivity testing, coupled with preventive treatment for those without evidence of active TB, efforts to improve treatment adherence, and implementation of infection control measures will reduce incidence of both drug-susceptible and drug-resistant TB. Retrospective studies such as this one provide a critical baseline from which progress can be measured, but prospective and complete epidemiologic surveillance, including molecular epidemiology, is crucially important to monitor, respond to and overcome the TB pandemic.

Back to Top | Article Outline

REFERENCES

1. Kvasnovsky CL, Cegielski JP, Erasmus R, et al. Extensively drug-resistant TB in the Eastern Cape, South Africa: high mortaltiy in HIV-negative and HIV-postive patients. J Acquir Immune Defic Syndr. 2011;57:146-152.

2. World Health Organization. Global Tuberculosis Control: WHO Report 2010. Geneva, Switzerland: World Health Organization; 2010.

3. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-1580.

4. Van Rie A, Warren R, Richardson M, et al. Classification of drug-resistant tuberculosis in an epidemic area. Lancet. 2000;356:22-25.

5. Harries AD, Hargreaves NJ, Gausi F, et al. High early death rate in tuberculosis patients in Malawi. Int J Tuberc Lung Dis. 2001;5:1000-1005.

6. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362:697-706.

7. Blanc FX, Sok T, Laureillard D, et al. Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. Abstract THLBB106. Presented at: XVIII International AIDS Conference; July 18-23, 2010; Austria, Vienna.

8. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798-1807.

9. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360:2397-2405.

10. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3:e466.

11. Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol. 2009;2:215-218.

12. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet. 2009;373:1183-1189.

13. Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008;12:128-138.

14. Banerjee A, Dubnau E, Quemard A, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 1994;263:227-230.

15. Barnard M, Albert H, Coetzee G, et al. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med. 2008;177:787-792.

16. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005-1015.

17. Jarand J, Shean K, O'Donnell M, et al. Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa. Trop Med Int Health. 2010;15:1179-1184.

18. Cohen T, Murray M, Wallengren K, et al. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med. 2010;7:e1000296.

19. Corbett EL, Bandason T, Duong T, et al. Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial. Lancet. 2010;376:1244-1253.

20. Shapiro A, Rakgokong M, Chaisson R, et al. Targeting at-risk households: intesified case finding for TB and HIV in contacts of TB patients in South Africa. Abstract #FRLBC106. Presented at: XVIII International AIDS Conference; July 18-23, 2010; Vienna, Austria.

© 2011 Lippincott Williams & Wilkins, Inc.

Login